中华临床免疫和变态反应杂志2013，Vol.7Issue(1)：16-21,6.
应用蛋白指纹图谱筛选肿瘤坏死因子抑制剂治疗类风湿关节炎的生物标志物
Screening for Specific Biomarkers in Tumor Necrosis Factor Inhibitor Treated Rheumatoid Arthritis Patients using Proteomic Fingerprint Technology
摘要
Abstract
Objective To screen for the potential protein biomarkers in rheumatoid arthritis (RA) patients who received tumor necrosis factor (TNF) monoclonal antibody ( infliximab) therapy by using proteomic fingerprint technology- Methods Seventeen RA patients with moderate to severe disease activity were enrolled in this Study- All patients were given an intravenous infusion of 200 mg infliximab at Week 0,2, 6, 14 and 22 , respectively. Clinical assessment was done at each visit. Serum samples were collected, and proteomic fingerprint technology combining magnetic beads with MALDI-TOFMS was used to analyze serum proteins. Results After infliximab treatment, 13 (76.5%) patients had clinical improvement, while 4 (23.5%) patients failed the treatment. Among those with clinical improvement, MALDI-TOFMS analysis showed 10 proteins decreased with infliximab treatment, while there was no change in those without improvement. Meanwhile, two kinds of proteins increased both in effective patients and non-effective patients. Conclusions Biomarkers for evahuation of efficacy of anti-TNF monoclonal antibody therapy can be discovered in serum by MALDI-TOF MS combining the use of magnetic beads. The pattern of combined markers provides possible predictors for efficacy of TNF inhibitor treatment.关键词
类风湿关节炎/肿瘤坏死因子抑制剂/蛋白组学Key words
rheurratoid arthritis/tumor necrosis factor inhihitor/paoteomic fingerprint technology分类
医药卫生引用本文复制引用
史群,林玮,胡朝军,白伊娜,张文,张奉春..应用蛋白指纹图谱筛选肿瘤坏死因子抑制剂治疗类风湿关节炎的生物标志物[J].中华临床免疫和变态反应杂志,2013,7(1):16-21,6.基金项目
国家自然科学基金面上项目(81172858) （81172858）
